Wedbush Reiterates an 'Outperform' on Biodel (BIOD); Comments on VIAjectT
Tweet Send to a Friend
Wedbush reiterates an Outperform rating on Biodel (Nasdaq: BIOD). Price target $17.
Wedbush analyst says, "VIAjectT ultra-rapid acting mealtime insulin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "VIAjectT ultra-rapid acting mealtime insulin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
